JD
Jacques Dumas
Chief ScientificOfficer

Jacques Dumas insider trades: Tetraphase Pharmaceuticals (TTPH) stock sales

Chief ScientificOfficer, Tetraphase Pharmaceuticals Last trade Jan 8, 2019 11 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
6
Open-market trades
since 2017
2
Companies
last trade 2019

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Jacques reports to the SEC

Open-market buys and sales

6 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jan 8, 2019TTPH↓ Sell10b5-1$12K
Jan 30, 2018TTPH↓ Sell10b5-1$54K
Jan 9, 2018TTPH↓ Sell10b5-1$45K
Oct 31, 2017TTPH↓ Sell10b5-1$53K
Aug 22, 2017TTPH↓ Sell10b5-1$105K
Aug 17, 2017TTPH↓ Sell10b5-1$42K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Jacques Dumas's insider trades

Jacques Dumas is Chief ScientificOfficer at Tetraphase Pharmaceuticals (TTPH). Since Aug 17, 2017, Jacques has reported no open-market purchases and 6 sales worth $311K on SEC Form 4. There have been no open-market trades in the last 12 months.

6 sales (100% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.

Their filings also include grants and awards (4 filings), option exercises (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TTPH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.